Anna Stachowiak

Anna Stachowiak

Auto-generated profile, based on publicly available information

Anna Stachowiak

Department of Clinical Pharmacy and Biopharmacy, Poznan University of Medical Sciences, Poznań, Poland

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2020 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
PDF file
AKAgnieszka Karbownik
Agnieszka Karbownik
JSJoanna Stanisławiak-Rudowicz
Joanna Stanisławiak-Rudowicz
ASAnna Stachowiak
Anna Stachowiak
MRMichał Romański
Michał Romański
EGEdmund Grześkowiak
Edmund Grześkowiak
ESEdyta Szałek
Edyta Szałek
Background and Objective Sorafenib is an oral, multikinase inhibitor with established single-agent activity in several tumor types. Sorafenib was moderately transported by P-glycoprotein (P-gp) and more efficiently by breast cancer resistance protein. The constitutive androstane receptor (CAR) is a ligand-activated transcription factor involved in P-gp regulation in the brain microvasculature. Paracetamol is a CAR activator. The purpose of this study was to investigate the effect of paracetamol on the brain uptake of sorafenib and sorafenib N-oxide. Methods The rats were assigned to two groups—rats receiving oral paracetamol 100 mg/kg and sorafenib 100 mg/kg (n = 42, ISR+PA) and rats receiving oral vehicle and sorafenib 100 mg/kg (n = 42, IISR). The sorafenib and sorafenib N-oxide concentrations in blood plasma and brain tissue were determined by a high-performance liquid chromatography method with ultraviolet detection. Brain-to-plasma partition coefficient (Kp) was calculated as a ratio of the area under the curve from zero to 24 h (AUC) in the brain and plasma. A drug targeting index (DTI) was estimated as the group ISR+PA Kp to group IISR Kp ratio. Results Pharmacokinetic analysis revealed increased brain exposure to sorafenib and sorafenib N-oxide after co-administration of paracetamol. The brain maximum concentration (Cmax) and the AUC of the parent drug in the ISR+PA group compared with the IISR group were greater by 49.5 and 77.8%, respectively, and the same parameters for the metabolite were higher by 51.4 and 50.9%. However, the Kp values of sorafenib and sorafenib N-oxide did not differ significantly between the two animal groups and the DTI values were close to 1. Conclusion Paracetamol increases exposure to sorafenib and sorafenib N-oxide in the brain, likely due to increased exposure in plasma.

8 January 2020 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
AKAgnieszka Karbownik
Agnieszka Karbownik
ASAnna Stachowiak
Anna Stachowiak
HUHanna Urjasz
Hanna Urjasz
KSKatarzyna Sobańska
Katarzyna Sobańska
ASAgnieszka Szczecińska
Agnieszka Szczecińska
ESEdyta Szałek
Edyta Szałek
Background Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resistant thyroid carcinoma. The TKI undergoes CYP3A4-dependent oxidative transformation, which may be influenced by hyperglycaemia. The aim of the study was to compare the oxidation for sorafenib between healthy and streptozotocin-induced diabetic rats. Additionally, the effect of sorafenib on glucose levels was investigated. Methods The rats were assigned to the groups: streptozotocin-induced diabetic (DG, n = 8) or healthy (HG, n = 8). The rats received sorafenib orally as a single dose of 100 mg/kg. The plasma concentrations of sorafenib and its metabolite N-oxide were measured with the validated high-performance liquid chromatography with ultraviolet detection. Results The difference between groups in Cmax and AUC0−t values for sorafenib were significant (p = 0.0004, p = 0.0104), and similarly for the metabolite (p = 0.0008, p = 0.0011). Greater exposure for the parent drug and analysed metabolite was achieved in diabetic group. However, the Cmax, AUC0−t, and AUC0−∞ ratios between the metabolite and sorafenib were similar in both groups. The significant reduction of glycaemia was observed only in the diabetic animals. Conclusion The findings of the study provide evidence that diabetes significantly influence on the exposition for sorafenib and its metabolite, but similar ratios N-oxide/sorafenib for AUC and Cmax in healthy and diabetic animals suggest that oxidation of the TKI is rather unchanged. Additionally, sorafenib-associated hypoglycaemia was confirmed in diabetic animals.

27 April 2020 in Farmacja Polska
Verified
Journal Article
Closed access
ABAdrian Bryła
Adrian Bryła
KUKamila Urbańczyk
Kamila Urbańczyk
ASAnna Stachowiak
Anna Stachowiak
MBMagdalena Burkacka
Magdalena Burkacka
MSMichał Steczko
Michał Steczko
AWAnna Wiela-Hojeńska
Anna Wiela-Hojeńska

5 September 2018 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Open access
PDF file
ASAnna Stachowiak
Anna Stachowiak
ESEdyta Szałek
Edyta Szałek
AKAgnieszka Karbownik
Agnieszka Karbownik
AŁAnna Łojko
Anna Łojko
JPJoanna Porażka
Joanna Porażka
EGEdmund Grześkowiak
Edmund Grześkowiak
Numerous studies have confirmed the influence of diabetes mellitus on the pharmacokinetics of drugs. Paracetamol (APAP) is an antipyretic that is commonly used in febrile neutropenia (FN) therapy. APAP is chiefly metabolised by glucuronidation and sulphation. This study assessed the influence of diabetes on the pharmacokinetics of paracetamol and its metabolites: glucuronide (APAP-glu) and sulfate (APAP-sulfate) in FN patients.

8 June 2021 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
AKAgnieszka Karbownik
Agnieszka Karbownik
ASAnna Stachowiak
Anna Stachowiak
HUHanna Urjasz
Hanna Urjasz
KSKatarzyna Sobańska
Katarzyna Sobańska
ASAgnieszka Szczecińska
Agnieszka Szczecińska
ESEdyta Szałek
Edyta Szałek
A correction to this paper has been published: https://doi.org/10.1007/s43440-021-00278-4